brain aneurysm: A congenital or acquired aneurysm within the cranium.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
332 |
4. Check minimum number of eventsNone |
332 |
5. Include endpointsNone |
332 |
6. Filter based on genotype QC (FinnGen only) |
332 |
Control definitions (FinnGen only)
- Control exclude
- I9_CEREBVASC
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- I67
- Name in latin
- Thrombosis non pyogenes systematis venosi intracranialis
Similar endpoints
↥List of similar endpoints to
Nonpyogenic thrombosis of intracranial venous system
based on the number of shared cases.
Similar with more cases:
- Cerebrovascular diseases (FINNGEN)
- Cerebrovascular diseases
- Neurological diseases, wide definition
- Cardiovascular diseases (excluding rheumatic etc)
- Cardiovascular diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1945 | 1146 | 787 |
| Only index persons | 1787 | 1081 | 706 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 47.77 | 44.15 | 53.10 |
| Only index persons | 47.16 | 43.52 | 52.73 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 332 | 218 | 114 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.05 |
| Median age at first event (years) | 48.97 | 44.93 | 56.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 302
- Matched controls
- 3018
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I67.6
ICD-10 Finland
Nonpyogenic thrombosis of intracranial venous system
+∞
323.0
301
*
B01AA03
ATC
warfarin; systemic
24.4
119.4
194
207
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
16.6
65.8
113
105
AA1AD
NOMESCO Finland
CT of head and brain
7.6
47.8
135
291
R51.80
ICD-10 Finland
Headache
7.2
43.9
127
277
B01AB05
ATC
enoxaparin; parenteral
5.6
40.4
158
495
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
442.0
40.1
39
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
21.7
38.5
57
32
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
334.1
30.4
30
*
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
39.3
28.1
35
10
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.4
25.8
74
146
XA800
NOMESCO Finland
Neuropsychological investigation
12.4
24.6
45
42
N03AX14
ATC
levetiracetam; systemic
16.3
21.8
35
24
K91
ICPC
Cerebrovascular disease
224.9
20.8
21
*
I63.6
ICD-10 Finland
Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
+∞
20.0
19
*
K90
ICPC
Stroke/cerebrovascular accident
59.1
19.2
22
*
XF400
NOMESCO Finland
ECG with 12 standard connections
4.4
19.0
77
219
K94
ICPC
Phlebitis/thrombophlebitis
19.1
18.6
28
16
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
7.8
17.9
42
61
I69.8
ICD-10 Finland
Sequelae of other and unspecified cerebrovascular diseases
+∞
17.9
17
*
H47.1
ICD-10 Finland
Papilloedema, unspecified
67.3
16.9
19
*
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
+∞
16.8
16
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.3
16.1
51
111
K99
ICPC
Cardiovascular disease other
11.3
15.1
28
27
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
19.6
14.9
22
12
G44.2
ICD-10 Finland
Tension-type headache
3.9
14.8
67
207
379
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
15.2
14.8
24
17
WX892
NOMESCO Finland
Monitored bed care
5.4
14.7
45
94
B01AB04
ATC
dalteparin; parenteral
7.9
14.5
33
46
R56.8
ICD-10 Finland
Other and unspecified convulsions
6.4
14.0
37
64
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
15.7
13.8
22
15
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.5
13.7
69
233
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
+∞
13.6
13
*
R4110
NOMESCO Finland
Physiotherapy
2.9
13.5
98
425
N03AF02
ATC
oxcarbazepine; oral
9.6
12.5
25
28
PA2AD
NOMESCO Finland
CT angiography of brain
39.3
12.3
15
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
13.2
12.3
21
17
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
12.1
83
345
A02BC02
ATC
pantoprazole; systemic
2.4
11.7
201
1373
R4120
NOMESCO Finland
Occupational therapy
5.2
11.6
36
76
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
17.9
11.3
17
10
R42
ICD-10 Finland
Dizziness and giddiness
3.0
11.1
72
287
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.2
11.0
42
111
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
10.2
10.9
21
22
AA1BD
NOMESCO Finland
Extensive CT of head and brain
10.2
10.9
21
22
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
22.4
10.8
15
7
PA2BG
NOMESCO Finland
MRI examination of vessels in the head with high intensity magnet
+∞
10.5
10
*
I67.7
ICD-10 Finland
Cerebral arteritis, not elsewhere classified
+∞
10.5
10
*
G93.2
ICD-10 Finland
Benign intracranial hypertension
+∞
10.5
10
*
I60.9
ICD-10 Finland
Subarachnoid haemorrhage, unspecified
+∞
10.5
10
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.4
10.5
53
178
R4150
NOMESCO Finland
Neuropsychological rehabilitation
27.0
9.9
13
5
D68.8
ICD-10 Finland
Other specified coagulation defects
15.7
9.6
15
10
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
9.5
132
784
I69.1
ICD-10 Finland
Sequelae of intracerebral haemorrhage
+∞
9.4
9
*
PA2BC
NOMESCO Finland
Cerebral extensive angiography with X-ray
+∞
9.4
9
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.5
9.1
17
17
G40.9
ICD-10 Finland
Epilepsy, unspecified
5.8
9.1
25
46
B01AB10
ATC
tinzaparin; parenteral
4.9
9.1
29
64
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
5.3
8.7
26
53
I82.88
ICD-10 Finland
Embolism and thrombosis of other specified veins
8.6
8.7
18
22
N02BE01
ATC
paracetamol; systemic, rectal
2.6
8.6
260
2138
I61.0
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, subcortical
+∞
8.4
8
*
I61.1
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, cortical
+∞
8.4
8
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.1
8.4
32
85
H02AB06
ATC
prednisolone; systemic
2.1
8.3
145
934
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.5
8.2
38
119
TAB00
NOMESCO Finland
Lumbar puncture
4.7
8.2
27
62
N03AB02
ATC
phenytoin; systemic
17.8
8.1
12
7
K78
ICPC
Atrial fibrillation/flutter
4.4
8.0
28
68
C10AA05
ATC
atorvastatin; oral
2.2
7.9
97
536
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
4.8
7.8
25
56
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.4
7.7
22
43
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
8.4
7.7
16
20
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
7.5
93
517
S01EC01
ATC
acetazolamide; systemic
8.7
7.4
15
18
G41.0
ICD-10 Finland
Grand mal status epilepticus
+∞
7.3
7
*
WX882
NOMESCO Finland
High dependency care
6.3
7.2
18
30
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
12.4
7.1
12
10
XCK00
NOMESCO Finland
Perimetry
4.1
7.1
26
67
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
14.2
6.9
11
8
R41.0
ICD-10 Finland
Disorientation, unspecified
9.6
6.9
13
14
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
17.2
6.8
10
6
AA5BD
NOMESCO Finland
CT of cerebral ischaemia
41.0
6.8
8
*
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.7
6.7
28
81
N03AG01
ATC
valproic acid; systemic, rectal
3.7
6.7
28
81
I67.9
ICD-10 Finland
Cerebrovascular disease, unspecified
71.3
6.4
7
*
A04AA02
ATC
granisetron; systemic, transdermal
4.0
6.3
24
64
WX002
NOMESCO Finland
Sedation and analgesia
2.3
6.3
59
285
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
+∞
6.3
6
*
I61.9
ICD-10 Finland
Intracerebral haemorrhage, unspecified
+∞
6.3
6
*
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
7.9
6.2
13
17
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.7
6.2
25
71
N03AX18
ATC
lacosamide; systemic
12.9
6.1
10
8
WX872
NOMESCO Finland
Intensive care
4.8
6.1
19
42
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.0
6.1
34
121
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
35
29.31
111.90
1.1
1.1
—
—
—
0
0
71
31
28.86
100.77
1.4
1.1
2.8
3.3
u/ml
0.21
37
13
67
30
27.73
94.00
1.4
1.1
3.3
1.4
u/ml
0.65
18
12
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
79
54
18.89
91.83
4.9
3.8
0.5
0.3
u/ml
4.26
65
31
82
72
14.80
82.54
5.2
3.2
185.4
178.6
%
0.24
82
72
34
12
31.45
51.00
1.4
1.2
—
—
—
0
0
174
664
4.41
39.76
3.0
2.0
138.9
315.7
u/l
1.05
166
626
30
17
19.30
37.25
1.2
1.1
1.0
1.1
ratio
—
7
6
150
594
3.78
30.89
3.9
1.8
2.3
1.2
mg/l
0.92
114
442
86
254
4.22
26.53
36.4
17.8
1.7
1.3
inr
—
10
39
105
382
3.56
23.69
5.5
4.5
0.8
0.8
mmol/l
0.00
99
360
242
1475
3.36
22.16
8.4
5.1
6.6
6.5
mmol/l
0.10
234
1350
21
20
11.14
19.30
1.4
1.2
—
—
—
0
0
207
1220
2.85
18.87
12.4
7.1
1.2
1.2
mmol/l
0.29
184
1033
18
15
12.63
17.94
2.4
1.9
11.8
12.0
umol/l
0.03
18
15
19
20
10.02
16.26
2.5
2.2
7.3
10.7
%
—
10
15
186
1097
2.58
15.99
12.4
6.5
1.2
1.2
mmol/l
1.37
173
999
77
292
3.13
15.63
9.6
7.4
1.1
1.1
mmol/l
0.27
72
273
30
57
5.69
15.44
1.7
1.2
12.8
2.5
e6/l
0.65
21
45
30
57
5.69
15.44
1.8
1.3
9304.4
138.1
e6/l
0.48
21
46
18
20
9.46
14.79
3.1
2.3
—
—
—
0
0
170
1013
2.39
13.60
8.7
5.3
35.0
36.1
g/l
1.72
164
938
204
1324
2.40
13.32
9.5
6.4
11.0
11.9
umol/l
0.48
196
1255
202
1314
2.37
12.99
11.6
5.7
28.1
29.0
%
0.57
195
1234
65
253
2.95
12.43
3.1
2.0
363.0
359.2
nmol/l
0.05
60
231
199
1302
2.32
12.41
11.0
5.5
57.1
56.5
%
0.24
193
1227
83
370
2.66
12.27
2.5
1.8
—
—
—
0
0
116
607
2.40
12.19
2.4
2.0
3.8
3.0
mg/l
1.07
97
523
94
448
2.53
12.10
5.6
3.7
94.0
355.9
ng/l
1.69
62
317
17
23
7.74
11.95
1.9
2.1
0.1
0.2
e9/l
0.17
12
16
65
262
2.84
11.62
2.3
1.8
—
—
—
0
0
17
24
7.41
11.52
1.8
2.1
422.5
484.3
e6/l
0.25
12
17
64
265
2.75
10.84
2.4
1.8
—
—
—
0
0
70
308
2.61
10.50
3.6
2.5
21.4
23.9
%
0.72
59
269
58
234
2.79
10.30
12.4
11.4
1.0
1.4
mmol/l
0.38
46
190
219
1579
2.14
9.63
16.5
8.9
4.2
4.0
e9/l
0.74
198
1387
17
30
5.92
9.37
1.0
1.0
—
—
—
0
0
33
101
3.52
9.31
13.1
14.3
24.4
24.6
mmol/l
0.14
33
93
259
2008
2.32
9.30
5.2
3.8
12.7
10.1
mm/h
2.00
242
1849
131
795
2.07
9.05
3.6
2.5
52.4
55.5
u/l
0.75
126
738
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
11
12
9.45
9.02
1.3
1.2
—
—
—
0
0
119
702
2.08
8.83
4.7
3.1
0.3
0.3
e6/l
0.03
88
518
78
393
2.29
8.59
3.5
3.1
3.4
2.6
e6/l
0.23
42
213
146
940
1.99
8.41
2.1
1.9
98.1
94.7
pmol/l
0.35
86
480
25
68
3.89
8.34
3.1
1.2
—
—
—
0
0
41
154
2.90
8.26
14.2
9.2
24.0
25.0
mmol/l
1.28
41
154
142
910
1.98
8.25
4.6
3.1
—
—
—
0
0
164
1106
1.95
8.20
3.0
2.4
75.8
75.6
nmol/l
0.03
144
998
14
24
6.05
7.92
1.2
1.1
—
—
—
0
0
14
24
6.05
7.92
1.2
1.1
—
—
—
0
0
177
1235
1.93
7.90
3.7
2.8
94.4
100.7
ug/l
0.19
164
1158
50
220
2.50
7.39
6.9
4.8
1.6
1.9
mmol/l
0.27
44
173
78
417
2.14
7.33
3.1
2.9
0.8
0.9
e6/l
0.11
41
237
252
2011
2.05
7.24
12.6
7.0
82.4
78.0
u/l
0.51
245
1882
76
407
2.12
7.10
1.5
1.6
1053.3
1227.2
nmol/l
0.92
54
307
32
115
2.97
6.96
1.9
1.6
—
—
—
0
0
12
20
6.19
6.95
1.2
1.1
—
—
—
0
0
136
900
1.87
6.88
4.7
3.2
32.0
31.2
u/l
0.08
130
856
173
1243
1.82
6.63
5.3
4.1
—
—
—
0
0
11
9
12.59
6.63
1.6
1.3
—
—
—
0
0
34
135
2.69
6.17
1.3
1.4
—
—
—
0
0
130
871
1.81
6.17
5.0
3.3
2.3
2.4
mmol/l
0.98
109
774
311
2758
3.02
6.13
26.5
12.0
20.7
21.3
mg/l
0.13
269
2107
91
550
1.90
5.97
1.6
1.5
18.7
21.0
nmol/l
0.95
84
476
58
300
2.13
5.87
2.9
3.5
9.0
8.6
umol/l
0.03
52
258
130
884
1.77
5.79
3.7
3.2
16.7
36.0
ng/l
2.88
75
534
24
82
3.08
5.70
2.4
2.2
—
—
—
0
0
37
162
2.44
5.52
1.8
1.5
—
—
—
0
0
310
2775
2.77
5.41
28.7
13.3
139.5
139.7
mmol/l
0.81
305
2696
24
85
2.97
5.37
1.9
2.2
1.3
4.2
ug/l
0.44
16
80
95
603
1.81
5.26
3.7
2.1
—
—
—
0
0
310
2783
2.72
5.22
29.2
13.4
3.9
4.0
mmol/l
1.91
303
2696
12
27
4.57
5.08
1.6
1.8
—
—
—
0
0
99
643
1.77
5.05
4.3
2.5
3408.9
7742.1
umol/l
0.59
84
569
19
63
3.14
4.75
1.5
1.2
—
—
—
0
0
9
11
8.37
4.59
1.3
1.2
—
—
—
0
0
13
34
3.94
4.58
2.8
1.4
—
—
—
0
0
23
88
2.73
4.50
10.8
5.3
9.5
8.9
kpa
0.85
23
80
21
77
2.84
4.44
1.9
1.5
0.0
0.1
iu/ml
—
6
13
14
40
3.61
4.38
3.6
2.5
16.9
16.7
%
—
7
19
10
22
4.66
4.33
1.4
2.1
380.2
483.9
e6/l
—
5
8
10
22
4.66
4.33
1.6
2.0
—
—
—
0
0
34
162
2.22
4.21
9.5
5.4
1.6
1.5
mmol/l
0.05
20
127
8
10
8.16
4.08
1.3
1.7
—
—
—
0
0
42
222
2.02
4.00
6.0
4.1
6.0
39.7
ug/l
0.52
37
173
225
1885
1.60
3.85
4.0
3.1
40.2
44.2
u/l
0.55
217
1780
16
55
3.01
3.79
1.5
1.2
—
—
—
0
0
16
55
3.01
3.79
1.5
1.2
—
—
—
0
0
34
170
2.11
3.75
9.8
5.3
5.0
5.2
kpa
0.69
34
156
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
8
12
6.80
3.69
1.3
2.8
233.8
119.0
%
—
8
12
9
17
5.41
3.53
5.2
2.1
—
—
—
0
0
8
13
6.27
3.52
1.0
1.0
—
—
—
0
0
30
147
2.14
3.49
2.8
2.4
11252.3
2179.0
u/l
0.73
13
53
44
253
1.85
3.29
3.7
3.2
—
—
—
0
0
17
66
2.66
3.27
2.9
1.7
—
—
—
0
0
14
49
2.94
3.23
2.9
2.0
129.2
132.5
g/l
—
9
33
11
34
3.31
3.08
2.9
1.3
—
—
—
0
0
283
2567
1.69
2.95
4.3
3.6
1.4
1.3
mmol/l
2.44
261
2384
7
13
5.48
2.88
1.4
1.5
—
—
—
0
0
7
13
5.48
2.88
1.4
1.5
—
—
—
0
0
74
513
1.57
2.80
1.4
1.7
474.6
443.3
pmol/l
0.36
61
443
13
48
2.78
2.75
2.4
1.7
—
—
—
0
0
161
1312
1.44
2.74
4.0
3.4
0.0
0.0
estimate
0.00
40
262
312
2926
2.10
2.73
17.2
9.3
27.0
25.9
u/l
0.52
304
2836
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
6
10
6.09
2.71
1.0
1.0
126.2
140.0
%
—
6
10
31
170
1.91
2.69
1.4
2.3
6.7
8.4
ug/l
0.23
25
150
16
67
2.46
2.67
3.0
1.7
—
—
—
0
0
160
1318
1.41
2.49
5.4
4.7
0.0
0.0
estimate
0.50
40
265
279
2550
1.59
2.48
5.6
4.6
1.7
1.8
mu/l
1.89
261
2357
240
2128
1.46
2.46
4.8
4.0
14.7
14.6
pmol/l
0.33
224
1952
161
1332
1.41
2.43
4.0
3.4
0.0
0.0
estimate
0.00
39
252
20
97
2.13
2.42
2.4
1.5
1.2
1.2
g/l
0.24
20
92
39
238
1.72
2.42
3.8
2.4
29.8
30.4
u/l
0.05
32
199
9
27
3.40
2.41
1.1
2.2
30.1
29.1
ug/l
—
9
27
5
8
6.32
2.38
1.8
1.6
—
—
—
0
0
62
429
1.55
2.35
4.7
2.8
2.4
2.4
mmol/l
0.29
53
366
18
85
2.18
2.33
1.9
1.9
—
—
—
0
0
12
47
2.61
2.29
3.2
1.5
—
—
—
0
0
82
607
1.47
2.26
2.4
3.1
1625.8
859.1
ng/l
0.72
67
504
30
173
1.81
2.26
5.0
4.6
68.4
71.5
ng/l
0.10
24
157
9
29
3.16
2.24
1.2
1.0
—
—
—
0
0
15
67
2.30
2.21
2.2
2.8
—
—
—
0
0
7
19
3.74
2.16
1.1
1.2
—
—
—
0
0
8
25
3.25
2.11
1.1
1.2
—
—
—
0
0
8
25
3.25
2.11
1.1
1.2
—
—
—
0
0
287
2669
1.56
2.04
4.9
4.1
4.6
4.7
mmol/l
0.67
267
2498
89
682
1.42
2.03
1.9
1.7
1.5
1.4
mmol/l
0.53
84
588
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
64
469
1.45
1.85
1.2
1.3
10.9
8.2
u/ml
0.13
22
182
6
17
3.57
1.84
1.2
1.2
—
—
—
0
0
6
17
3.57
1.84
1.2
1.2
—
—
—
0
0
16
80
2.05
1.83
2.2
1.8
—
—
—
0
0
263
2419
1.42
1.83
6.0
5.1
39.1
38.9
mmol/mol
0.07
244
2276
7
23
3.09
1.81
1.0
5.3
99.4
95.7
%
—
7
23
284
2656
1.48
1.74
4.9
4.0
1.4
1.5
mmol/l
1.66
261
2479
65
484
1.43
1.73
1.3
1.3
17.1
26.5
iu/ml
1.08
17
152
5
13
3.89
1.72
2.8
1.5
—
—
—
0
0
5
13
3.89
1.72
1.4
7.8
—
36.4
u/ml
—
0
5
10
42
2.42
1.69
1.8
1.5
—
—
—
0
0
33
215
1.59
1.64
2.8
2.3
—
15.3
—
0
11
5
14
3.61
1.62
2.8
1.4
—
—
—
0
0
5
14
3.61
1.62
1.2
1.0
—
—
—
0
0
15
77
1.99
1.62
1.5
1.4
—
—
—
0
0
22
129
1.76
1.61
2.5
1.8
—
—
—
0
0
20
114
1.80
1.60
6.5
3.5
1.5
1.3
%
0.25
20
114
288
2712
1.47
1.58
5.4
4.4
2.8
2.8
mmol/l
0.56
268
2526
277
2595
1.41
1.52
4.6
4.1
5.9
5.8
mmol/l
0.09
249
2388
12
59
2.07
1.45
1.2
1.2
—
—
—
0
0
5
16
3.16
1.44
2.2
2.9
395.6
675.3
u/ml
—
5
16
15
81
1.89
1.42
1.1
1.1
—
—
—
0
0
270
2530
1.36
1.38
21.7
10.6
86.9
86.4
ml/min/173m2
0.14
242
2039
6
24
2.53
1.31
1.0
1.1
—
77.6
—
0
5
277
2614
1.36
1.28
29.8
13.0
39.6
40.1
%
0.54
200
2027
8
35
2.32
1.27
2.6
1.5
—
—
—
0
0
28
188
1.53
1.26
2.4
3.6
4.2
4.6
pmol/l
1.06
22
165
8
39
2.08
1.16
1.0
1.1
—
—
—
0
0
5
20
2.52
1.15
3.6
1.4
—
—
—
0
0
36
263
1.41
1.09
1.5
1.9
—
—
—
0
0
7
33
2.14
1.06
3.0
1.8
—
—
—
0
0
29
205
1.45
1.05
1.4
1.8
—
—
—
0
0
81
676
1.26
1.01
1.3
1.3
0.8
0.9
u/ml
0.13
26
175
9
49
1.86
0.99
7.9
3.0
41.8
34.3
u/ml
—
9
49
5
23
2.19
0.98
1.0
1.0
—
—
—
0
0
5
23
2.19
0.98
1.4
1.2
—
—
—
0
0
10
54
1.88
0.97
2.2
1.9
—
—
—
0
0
119
1044
1.22
0.94
4.4
3.4
—
—
—
0
0
6
27
2.24
0.94
6.3
3.1
25.3
43.8
u/ml
—
6
27
13
206
0.62
0.92
1.6
1.6
—
—
—
0
0
8
43
1.88
0.88
2.9
1.7
—
—
—
0
0
27
196
1.41
0.87
5.1
2.5
79.8
70.4
ml/min/173m2
1.14
18
71
8
44
1.84
0.86
1.5
1.4
—
—
—
0
0
14
89
1.60
0.82
1.4
1.3
—
—
—
0
0
5
25
2.01
0.73
2.6
1.7
—
—
—
0
0
7
40
1.77
0.71
1.9
1.3
—
—
—
0
0
7
40
1.77
0.71
1.9
1.3
—
—
—
0
0
7
41
1.72
0.70
1.9
1.3
—
—
—
0
0
7
41
1.72
0.70
1.9
1.3
—
—
—
0
0
7
41
1.72
0.70
1.9
1.3
—
—
—
0
0
7
41
1.72
0.70
1.9
1.3
—
—
—
0
0
5
27
1.86
0.68
1.2
1.6
—
—
—
0
0
10
64
1.58
0.59
1.4
1.4
—
—
—
0
0
8
124
0.64
0.55
1.4
1.6
—
—
—
0
0
57
498
1.17
0.48
4.7
4.1
21.2
22.4
%
0.18
24
219
78
700
1.15
0.47
4.6
3.6
0.0
0.0
estimate
0.50
38
259
8
117
0.68
0.46
1.3
1.4
—
—
—
0
0
8
117
0.68
0.46
1.3
1.4
—
—
—
0
0
8
118
0.67
0.46
1.3
1.4
—
—
—
0
0
8
118
0.67
0.46
1.3
1.4
—
—
—
0
0
5
84
0.59
0.46
2.0
1.8
—
—
—
0
0
7
51
1.38
0.44
1.3
1.1
—
—
—
0
0
8
56
1.44
0.43
1.8
1.6
—
—
—
0
0
10
70
1.44
0.42
2.3
1.6
—
—
—
0
0
5
33
1.52
0.41
2.0
1.2
—
—
—
0
0
61
544
1.15
0.40
1.3
1.5
—
—
—
0
0
7
105
0.66
0.40
2.0
1.8
—
—
—
0
0
13
98
1.34
0.38
2.1
1.6
—
—
—
0
0
8
112
0.71
0.38
1.5
1.4
—
—
—
0
0
9
69
1.31
0.37
1.7
1.4
—
—
—
0
0
33
282
1.19
0.37
4.6
3.9
29.5
31.9
%
0.54
22
185
11
142
0.77
0.31
1.3
1.5
—
—
—
0
0
208
2013
1.09
0.29
3.6
3.5
—
—
—
0
0
7
57
1.23
0.29
2.0
1.2
—
—
—
0
0
68
629
1.10
0.26
4.8
4.5
1.8
2.4
ug/l
0.45
61
559
14
168
0.83
0.23
1.1
1.3
—
—
—
0
0
5
39
1.29
0.23
2.8
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
19.5
—
0
12
61
652
0.92
0.20
2.1
1.6
—
—
—
0
0
40
368
1.10
0.18
3.4
2.8
0.8
0.7
ug/l
0.08
31
229
25
226
1.11
0.15
1.5
1.2
136.2
181.7
iu/ml
—
5
90
14
121
1.16
0.15
1.1
1.5
—
—
—
0
0
6
58
1.04
0.08
3.2
2.7
24.5
56.1
ug/min
—
6
35
28
289
0.97
0.02
1.3
1.7
—
—
—
0
0
28
286
0.98
0.00
6.4
6.2
—
—
—
0
0
46
458
1.01
0.00
2.1
2.1
—
—
—
0
0
41
415
0.99
0.00
2.0
2.0
—
—
—
0
0
15
154
0.97
0.00
1.1
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.7
1.5
—
—
—
0
0
9
95
0.95
0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
2.2
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
94
0.96
0.00
1.1
1.1
—
—
—
0
0
9
98
0.92
0.00
1.8
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
7.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint I9_THROMBICV and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_THROMBICV | 2.151 [1.58, 2.92] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.19 |
During the follow-up period (1.1.1998 — 31.12.2019), 100 out of 916 females with I9_THROMBICV died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_THROMBICV | 2.538 [1.86, 3.46] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 119 out of 619 males with I9_THROMBICV died.
Mortality risk
Mortality risk for people of age
years, who have I9_THROMBICV.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.224% | 0.476% |
| 5 | 1.437% | 3.118% |
| 10 | 3.209% | 7.444% |
| 15 | 5.841% | 13.79% |
| 20 | 10.125% | 22.083% |
Relationships between endpoints
↥Index endpoint: I9_THROMBICV – Nonpyogenic thrombosis of intracranial venous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data